Epilepsy is a serious neurological condition characterized by recurrent unprovoked seizures. The exact etiology of epilepsy is not fully understood. Here, we demonstrated that the expression of contactin-associated protein-like 4 (CNTNAP4) was decreased in the temporal neocortex of epileptic patients and in the hippocampus and cortex of epileptic mice. Lentivirusmediated knock-down of CNTNAP4 in the hippocampus increased mice susceptibility to epilepsy. Conversely, lentivirusmediated overexpression of CNTNAP4 decreased epileptic behavior in mice. CNTNAP4 affected neuronal excitability and inhibitory synaptic transmission via postsynaptic receptors in Mg 2+ -free epilepsy cell model. Down-regulation or overexpression of CNTNAP4 in the hippocampus influenced the expression of gamma-aminobutyric acid A receptor β2/3 (GABA A Rβ2/3) membrane protein, without affecting total GABA A Rβ2/3 protein concentration in epileptic mice. Protein interactions between CNTNAP4, GABA A Rβ2/3 and gamma-aminobutyric acid receptor-associated protein (GABARAP) were observed in the hippocampus of epileptic mice. These findings suggest CNTNAP4 may be involved in the occurrence and development of epilepsy through the regulation of GABA A R function, and may be a promising target for the development of epilepsy treatment.
Introduction
Epilepsy is a serious neurological disorder that affects approximately 65 million people worldwide (Thurman et al. 2011) . It is characterized by seizures of unpredictable frequency that has the ability to affect patients of all ages, races and genders. Epilepsy comprises several types of seizures that can severely impact the patients' quality of life, as well as their physical and psychological health. The rate of sudden unexpected death in epilepsy patients (SUDEP) is 2-3 times higher than the rate of sudden unexpected death in the general population (Arida et al. 2008; Tomson et al. 2008) . Treatment with antiepileptic drugs (AEDs) improves the symptomatic recurrence of epileptic seizures, but does not provide an ultimate cure. However, the medical care cost of AEDs is significant. Furthermore, approximately 20-40% of epileptic patients fail to respond to AEDs and develop refractory epilepsy (French 2007) . Therefore, epilepsy imposes a significant burden on patients, their families, and society. Moreover, the exact diagnosis of epileptic seizures is often challenging, though the advances in electroencephalogram (EEG) have greatly improved the diagnosis rate of epileptic events (Baysal-Kirac et al. 2016; Wyman et al. 2016) . It is, therefore, hoped that studies investigating the definitive pathogenesis and mechanisms underpinning epilepsy will ultimately improve diagnosis and lead to the development of more effective therapeutic strategies.
The exact etiology and pathogenesis of epilepsy is not fully understood. Epilepsy can be attributed to alterations in the synchronization in cortical neurons (Zhong et al. 2011) . Gammaaminobutyric acid (GABA) is the major inhibitory neurotransmitter in the brain and its imbalance can lead to the development of epileptic seizures (Karayannis et al. 2014) . Experimental and clinical evidence suggested that GABAergic synaptic transmission plays an important role in the pathogenesis and treatment of epilepsy and GABA A receptor agonists can enhance GABAmediated inhibition (Treiman 2001; Lancaster et al. 2010) . Contactin-associated protein-like 4 (CNTNAP4) is predominantly expressed in the central nervous system and interacts with calcium/calmodulin-dependent serine protein kinase (CASK). This interaction is important for neurological development and synaptic function (Huang et al. 2010) . Indeed, recent studies indicated that CNTNAP4 may be associated with autism (Wang et al. 2010; O'Roak et al. 2012) , childhood-onset schizophrenia (Rudd et al. 2015) , and aging in females (Iakoubov et al. 2013) . Additionally, Karayannis et al. recently reported that CNTNAP4 contributes to GABAergic synaptic transmission, and CNTNAP4 knock-out mice exhibit autistic-like behavior (Karayannis et al. 2014) . Furthermore, recent reports indicated that alterations in activity of GAB A ARs containing β3 subunits and the dysfunction of GABA-mediated inhibitory signaling were associated with autism spectrum disorders as well as an increased sensitivity to seizures (Vien et al. 2015; Nakamura et al. 2016) . Therefore, we speculated that CNTNAP4 gene may participate in the development of epilepsy by regulating GABA or GABA receptor function.
Temporal lobe epilepsy (TLE) is the most common type of refractory epilepsy (Téllez-Zenteno and Hernández-Ronquillo 2012) . In this study, we explored the association between CNTNAP4 expression and epilepsy in patients presented with TLE as well as pentylenetetrazole kindling and pilocarpineinduced epileptic mouse models. Additionally, we observed the behavioral changes in epileptic mice upon transfection with lentivirus-mediated interference or overexpression of CNTNAP4 gene in the hippocampus. Furthermore, whole-cell patch-clamp and co-immunoprecipitation were used to investigate the underlying mechanism of CNTNAP4.
Materials and Methods

Subjects and Specimens
The present study was approved by the Institutional Ethics Committee of the First Affiliated Hospital of Chongqing Medical University. All enrolled patients or their family members signed an informed written consent. A total of 20 patients (9 males and 11 females) with a mean age of 27.10 ± 7.62 years (ranging between 10 and 40 years old) were enrolled from Beijing Tiantan Hospital, Beijing Xuan Wu Hospital, and The First Affiliated Hospital of Chongqing Medical University, China between 2011 and 2014. All patients were diagnosed with TLE and subsequently underwent surgical resection. TLE was diagnosed based on the proposed classification for epileptic seizures by the International League Against Epilepsy (ILAE) in 2001 (Engel, 2001) . All patients presented with refractory complex partial seizures arising from the mesial temporal lobe. Clinical symptoms and EEG recordings were independently examined by experienced neurologists. Specimens were obtained from the resected epileptic focus located in the temporal neocortex, and histopathological profiles were reassessed by independent neuropathologists. The epileptic duration since the initial onset of symptoms until the time of the surgery ranged from 4 years to 27 years (mean, 13.35 ± 6.74 years). All patients were unresponsive to 3 or more AEDs at maximum therapeutic dosages. All patients experienced a seizure within 1 week before surgery.
Control specimens were collected from patients with traumatic brain injury in the First Affiliated Hospital of Chongqing Medical University, China. Control patients included 4 males and 6 females, with a mean age of 33.30 ± 5.67 years (range, 26-44 years old). The inclusion criteria included: (1) no history of epilepsy; (2) no previous AED use; (3) no remarkable abnormal findings in postoperative histopathological examinations; and (4) informed consent was obtained from the patients or their relatives.
Epilepsy Model Induction and Grouping
Animal experiments were approved by Institutional Animal Ethics Committee of the First Affiliated Hospital of Chongqing Medical University, China; following the NIH Guidelines for the Care and Use of Laboratory Animals. All measures were taken to decrease animal discomfort. Specific pathogen-free (SPF) C57BL/6 male mice (19-23 g) were used for the study. The mice were maintained in polypropylene cages at a temperature of 23 ± 1°C in a clean environment under a 12-h light/dark cycle, with free access to food and water. Mice were randomly divided into 2 groups: (1) pentylenetetrazole (PTZ) kindling epileptic mouse model and (2) pilocarpine-induced epileptic mouse model. Model induction was performed in a SPF grade laboratory.
In the PTZ model, PTZ (35 mg/kg) was administered by intraperitoneal (i.p) injection to the mice once daily for 3 weeks. One hour after each PTZ injection, evoked behavioral seizures were evaluated based on the Racine's standard scale: stage I, immobility and staring; stage II, rigid posture; stage III, repetitive movements and head bobbing; stage IV, rearing and myoclonic twitching ( Fig. 4k ) and stage V, severe tonic-clonic seizures (Fig. 4l) . Mice that reached stages IV and V in 5 consecutive days were recruited as established kindling models (n = 11). The mice that were not kindled by PTZ were used as the control group (n = 11). The mortality rate of the PTZ model was approximately 40% in our study. In the pilocarpine-induced epilepsy model, each mouse received an i.p. injection of atropine (1 mg/kg) to block the peripheral effects of pilocarpine. Next, 30 min later, we administered pilocarpine (320 mg/kg; i.p) to induce status epilepticus. Subsequently, mice were given an i.p. injection of diazepam (10 mg/kg) to stop seizures 1 h after the onset of pilocarpineinduced status epilepticus. After the induction of status epilepticus, surviving mice presented with spontaneous recurrent seizures (SRSs) were defined as the experimental group (n = 11) and mice without SRSs (non-SRSs) were defined as the control group (n = 11). Twenty-four-hour video recording was used to monitor the changes in epileptic behavior and to evaluate SRS animals for 1 month. Seizures were assessed based on the Racine scale. The mortality rate of pilocarpine-induced epileptic model reached 50% in our experimental model.
Construction of Lentiviral Vectors
Lentivirus vectors for CNTNAP4 RNA interference (LV-CNTNAP4-RNAi) and lentivirus vectors for CNTNAP4 overexpression (LV-CNTNAP4) were constructed according to the manufacturer's protocol (GeneChem Inc.). The sequence of LV-CNTNAP4-RNAi was as follows: TGTCACTAAGATTGTGATT; the titer of the lentiviral vectors was 5E + 8 Tu/ml. The overexpression vector LV-CNTNAP4 was amplified using the following primers:
5′-GAGGATCCCCGGGTACCGGTCGCCACCATGAATATGGGAT CTGTCGCT-GGAGCTG-3′ and 5′-TCCTTGTAGTCCATACCGGT GAAGAAATACTCTTTCTGA-TTTTCACCGAC-3′. The amplified gene was transferred into the lentivirus vectors according to the manufacture's protocol and the titer was 2E + 7 Tu/ml. Lentivirus vectors coding for GFP only were used as control vectors; LV-GFP and LV-GFP′ for LV-CNTNAP4-RNAi and LV-CNTNAP4, respectively.
Intrahippocampal Injection of Lentiviral Vectors
Intrahippocampal injection with lentiviral vectors was performed using a stereotaxic apparatus (Stoelting Co. Ltd). Following anesthesia, mice (n = 7) were placed in the stereotaxic frame and 2 μL lentiviral vectors (LV-CNTNAP4-RNAi/LV-CNTNAP4) or empty lentiviral vectors (LV-GFP/LV-GFP′) were injected (0.5 μL/min) bilaterally into the dentate gyrus (anterior/ posterior: 2.0 mm, medial/lateral ±1.5 mm, and dorsal/ventral: 2.0 mm) using a glass microsyringe. Following injection, the microsyringe was left for 5 min in situ to prevent the backflow of lentiviral vectors and to promote full absorption.
Fourteen days after the intrahippocampal injection, 2 mice were randomly selected from each experimental group and analyzed for green fluorescence expression to verify successful lentivirus infection in the hippocampus. The other 5 mice in each group were used for quantitative real-time polymerase chain reaction (qRT-PCR) and western blot analysis to evaluate the efficiency of lentiviral interventions. Brain specimens were immediately placed in liquid nitrogen after sacrifice until needed.
Behavioral Analysis
Fourteen days after intrahippocampal injections of lentiviral vectors in mice (n = 7-9 per group), seizures were induced using the epilepsy models as aforementioned. For behavioral analysis in the PTZ kindling epileptic model, we evaluated evoked seizures based on Racine's standard scale every 24 h, as well as the latency of kindling. For behavioral analysis in the pilocarpine-induced epilepsy model, we used video monitoring to observe SRSs for 1 month and recorded the latency and frequency of SRSs of stage IV or V (Racine's standard scale) animals (see Supplementary Methods). Mice were sacrificed 6 weeks after the intrahippocampal injections, and bilateral hippocampi were collected for further experimental analyses.
In Vivo EEG Recording
Following 3.5% chloral hydrate (0.01 mL/g) anesthesia, an intracranial electrophysiological recording microwire array (Plexon) was implanted into the CA1 region of the right hippocampus (anterior-posterior: −2.0 mm, medial-lateral: +1.5 mm, and dorsal-ventral: −1.5 mm), and the array was fixed on the skull using dental cement. EEG tracings of pilocarpine-induced epilepsy in mice were recorded. EEG data were recorded for 8 h daily for 7 days, beginning at 08:00 am to exclude the interference of circadian rhythms. EEG signals were filtered at 0.1-1000 Hz, amplified 1000 times, and digitized at 4 kHz. An electrophysiological seizure was defined as high amplitude (>2 times baseline), high frequency (>5 Hz), and lasting longer than 5s (Jimenez-Mateos et al. 2012 ).
Electrophysiological Analysis
Fourteen days after lentiviral transfection, mice were anesthetized by i.p. injection of 3.5% chloral hydrate (0.01 mL/g) and electrophysiological analysis was performed on mouse brain slices as previously described .
To record extracellular electrophysiological changes, glass electrodes (3-5 MΩ) were filled with artificial cerebral spinal fluid (ACSF; 124 mM NaCl, 3 mM KCl, 1.23 mM NaH 2 PO 4 , 2 mM MgCl 2 , 2 mM CaCl 2 , 26 mM NaHCO 3 , 10 mM glucose, pH 7.4) and placed in the CA1 cell layer. Spontaneous epilepsy was induced using Mg 2+ -free ACSF. To measure cellular excitability, a whole-cell current clamp was used to record the action potentials (AP) in CA1 region as previously described ; the miniature excitatory postsynaptic currents (mEPSCs) recording, the miniature inhibitory postsynaptic currents (mIPSCs) recording and evaluation of the presynaptic GABAergic activities were performed using the paired pulse protocol; the paired pulse ratio (PPR) was measured as described previously ; Supplementary Methods). Gabazine acts as an antagonist at the GABA A receptors. To determine the ability of CNTNAP4 in altering the phasic GABAergic synaptic current or tonic GABA-ergic current, a lower concentration of gabazine (200 nM, Abcam; ab144487) was infused into Mg 2+ -free ACSF to selectively inhibit the phasic GABA-ergic synaptic current. Variations in mIPSCs were recorded in the pyramidal neurons before and after gabazine administration.
Electrophysiological data were collected using a Multiclamp 700B amplifier (Axon). Electrophysiological signals were filtered at 2 kHz and sampled at 10 kHz. Data were collected 5 min after the currents were stably maintained. Additionally, the data were discarded if the series resistance was changed by over 15%. Mini Analysis 6.0.1 and Clamp Fit 10.3 software (Axon) was used to analyze the recorded data. OriginPro 9.2 software (OriginLab) was used to convert data to the graphical format.
qRT-PCR Analysis of CNTNAP4
Total RNA was extracted from the brain tissues of TLE patients and control subjects, as well as the hippocampi and cortices of epileptic mice according to standard protocols. Next, cDNA was synthetized using Hiscript II qRTSuper Mix (Vazyme). Real-time PCR was performed using an Ace Q TM qPCR SYBR Green Master Mix (Vazyme) and the iQ5 Real-Time PCR detection system (BioRad Laboratories). PCR primer sequences for CNTNAP4 mRNA amplification are listed in Table 1 . The primer sequences for human and mouse CNTNAP4 were obtained from the PrimerBank, ID numbers 148664241c3 and 31982591a1, respectively.
Relative mRNA levels were determined by the average cycle threshold value (Ct) followed by normalization for the housekeeping gene GAPDH. The fold changes of CNTNAP4 were quantified by using the 2 −ΔΔCt method: and Schmittgen 2001) .
Western Blot Analysis
Western blot analysis was performed according to published protocols . A RIPA protein extraction kit (Beyotime Institute of Biotechnology) was used to extract total proteins according to the manufacturer's instructions. An enhanced BCA Protein Assay Kit (Beyotime Institute of Biotechnology) was used to determine protein concentrations. The following primary antibodies were used in this study: rabbit anti-CNTNAP4 (1:100, Beijing Biosynthesis Biotech Co., Ltd; bs-11076R), rabbit anti-GABA A Rβ2/3 (1:100, Beijing Biosynthesis Biotech Co., Ltd; bs-12066R), mouse anti-GAPDH (1:2000, Thermo Scientific; 437000) and rabbit anti-β-actin (1:500, Proteintech Group, Inc.; 20536-1-AP). An enhanced chemiluminescence substrate kit (Beyotime Institute of Biotechnology Nantong) was used to visualize protein bands before digital scanning (FUSION-FX5, Vilber Lourmat). Fusion Capt Advance FX5 software (Vilber Lourmat) was used to quantify the pixel density of protein bands.
Immunofluorescence Staining
Mice were anesthetized by i.p. injection of 3.5% chloral hydrate (0.01 mL/g) and perfused with 50 mL saline followed by 100 mL 4% paraformaldehyde through the ventriculus sinister to obtain the best possible preservation of the brain. Brain tissues were fixed with 4% paraformaldehyde, and serial 10 μm thick frozen coronal sections were obtained. Immunofluorescence staining was performed as detailed previously (Zhang et al. 2015) . The following primary antibodies were used: rabbit anti-CNTNAP4 
Co-immunoprecipitation
Co-immunoprecipitation was performed to determine proteinprotein interactions between CNTNAP4 and GABA A Rβ2/3 or GABARAP. Hippocampal tissue (30 mg) from the pilocarpineinduced epileptic mice was homogenized with RIPA lysis buffer (Beyotime Institute of Biotechnology). Next, equal amounts of proteins were incubated with 2.5 μL rabbit IgG (1:100, Abcam) as a polyclonal-isotype control or 10 μL rabbit anti-CNTNAP4
(1:200, Beijing Biosynthesis Biotech Co., Ltd) or 10 μL rabbit anti-GABA A Rβ2/3 (1:200, Beijing Biosynthesis Biotech Co., Ltd) or 10 μL rabbit anti-GABARAP (1:200, Beijing Biosynthesis Biotech Co., Ltd; bs-12082R) for 4 h at 4°C. Subsequently, the mixture was incubated with 30 μL protein A + G agarose beads (Beyotime Institute of Biotechnology) at 4°C overnight. The mixtures were centrifuged (2500 rpm, 5 min, 4°C) and the beads were rinsed 5 times with phosphate-buffered saline (PBS). Next, immunocomplexes were boiled with 1× Western blot loading buffer for 5 min. Western blot was performed with the abovementioned antibodies.
Biochemical Measurement of Surface-expressed Receptors
Biochemical measurement of surface-expressed receptors was performed in the hippocampi of pilocarpine-induced epileptic mice following lentiviral infection as reported previously . Protein concentrations were determined using the enhanced BCA Protein Assay Kit (Beyotime Institute of Biotechnology). Samples were then boiled with 1× Western blot loading buffer for 5 min. Quantitative western blot analysis was performed for surface proteins.
Statistical Analysis
All data are presented as the means ± standard error. We performed statistical analysis using the Statistical Package of Social Sciences (SPSS, version 18.0). Student's t test was used to compare the experimental results between the different groups. Chi-squared test was used to compare the gender between TLE patients and controls. P value <0.05 was considered to be statistically significant. GraphPad Prism 5.0 software (GraphPad Software) was used to design the statistical graphs.
Results
Decreased Expression of CNTNAP4 in the Temporal Neocortex of TLE Patients
The detailed clinical and demographic characteristics of TLE patients and control subjects are summarized in Tables 2 and  3 , respectively. There was no statistically significant difference in the sex or age among subjects of the TLE and control groups (P > 0.05). The expression of CNTNAP4 mRNA in the temporal neocortex of TLE patients was significantly lower than that in control subjects (P < 0.01; Fig. 1a) . Similarly, western blot analysis verified that the expression of CNTNAP4 protein in the temporal neocortex of TLE patients was significantly lower than that in control subjects (P < 0.05; Fig. 1b) . Immunofluorescence staining demonstrated that CNTNAP4 co-localized with the neuronal dendrite marker MAP2. While, the co-localization of CNTNAP4 and the glial cell marker GFAP was not detected (Fig. 1c) . Additionally, CNTNAP4 was also co-localized with the inhibitory neuronal marker GAD67 and inhibitory postsynaptic marker Gephyrin (Fig. 1d) . Conversely, CNTNAP4 did not colocalize with the excitatory neuronal marker VGLUT1 or the excitatory postsynaptic marker PSD95 (Fig. 1e) . It is worth mentioning that the localization of CNTNAP4 in the brain of control subjects was similar to TLE patients (see Supplementary  Fig. S2 ). 
Decreased Expression of CNTNAP4 in PTZ and Pilocarpine-induced Epileptic Mice
In PTZ kindling epileptic mice, the expression of CNTNAP4 mRNA was significantly lower in the temporal cortex and hippocampus compared with that in the control group (P < 0.05; Fig. 2a) . Similarly, the expression of CNTNAP4 protein in the temporal cortex and hippocampus was also significantly lower in epileptic mice compared with the control mice (P < 0.05; Fig. 2c,d) . In pilocarpine-induced epileptic mice, the expression of CNTNAP4 mRNA and CNTNAP4 protein were significantly lower in the temporal cortex and hippocampus of the SRSs group compared with the non-SRSs group (P < 0.05; Fig. 2b,e,f) .
Next, we examined the overall localization of CNTNAP4 in the hippocampi of epileptic and control mice (see Supplementary Fig. S3a ). The localization of CNTNAP4 was similar between epileptic and control mice (see Supplementary  Fig. S3b-e) . In epileptic mice, immunofluorescence staining verified that CNTNAP4 co-localized with MAP2 in the temporal cortex and hippocampus, but did not co-localize with GFAP ( Fig. 2g and h). Furthermore, CNTNAP4 also co-localized with GAD67 and Gephyrin (Fig. 2j) , but did not co-localize with VGLUT1 or PSD95 (Fig. 2i,k) .
Effect of LV-CNTNAP4-RNAi and LV-CNTNAP4 on Epileptic Mice
Fourteen days following the injection of LV-CNTNAP4-RNAi and LV-CNTNAP4 lentiviral vectors, GFP autofluorescence was detected in the mouse hippocampus indicating successful lentiviral infection (Fig. 3a) . Compared with the control group, mice infected with LV-CNTNAP4-RNAi showed significantly lower expression of CNTNAP4 mRNA (P < 0.01; Fig. 3b ) and lower expression of CNTNAP4 protein (P < 0.01; Fig. 3c ). In contrast, mice injected with LV-CNTNAP4 showed significantly higher expression of CNTNAP4 mRNA (P < 0.01; Fig. 3b ) and CNTNAP4 protein (P < 0.05; Fig. 3d ). These findings indicated the injection of LV-CNTNAP4-RNAi and LV-CNTNAP4 into the hippocampus effectively intervened with the endogenous expression of CNTNAP4 and subsequently affected CNTNAP4-associated proteins in hippocampus without affecting its level in the temporal cortex (see Supplementary Fig. S5 ). Furthermore, 6 weeks after the injection of lentiviral vectors, western blot analyses demonstrated that the expression of CNTNAP4 protein in LV-CNTNAP4-RNAi group was significantly lower than the control group (LV-GFP) (P < 0.01; Fig. 3e ). Conversely, CNTNAP4 protein was significantly higher in the LV-CNTNAP4 group compared with the control group (LV-GFP') (P < 0.05; Fig. 3f ). These findings indicate the stability of the lentiviral vectors. Next, we analyzed the behavioral data for PTZ kindling epileptic mice (Fig. 4a) and pilocarpine-induced epilepsy mice CNTNAP4 co-localized with the neuronal dendrite marker microtubule-associated protein 2 (MAP2), while no co-localization of CNTNAP4 and the glial cell marker GFAP was detected. (d) CNTNAP4 co-localized with the inhibitory neuronal marker GAD67 and inhibitory postsynaptic marker Gephyrin. (e) CNTNAP4 did not colocalize with excitatory neuronal marker VGLUT1 and excitatory postsynaptic marker PSD95. Scale bar 50 μm. *P < 0.05, **P < 0.01. (Fig. 4f) . According to Racine's standard scale, LV-CNTNAP4-RNAi injection resulted in a higher daily seizure scores in the PTZ kindling epileptic mice compared with the LV-GFP controls (Fig. 4b) . Furthermore, the latency of kindling in epileptic mice was significantly shorter than that of the control group (P < 0.01; Fig. 4d ). On the other hand, the injection of LV-CNTNAP4 resulted in lower daily seizure sores in PTZ kindling epileptic mice compared with LV-GFP′ controls (Fig. 4c) , and the latency of kindling in epileptic mice was significantly longer than that of the control group (P < 0.01; Fig. 4e ). In pilocarpine-induced epilepsy, the knock-down of CNTNAP4 led to more frequent SRSs in LV-CNTNAP4-RNAi group compared with the LV-GFP controls (P < 0.01; Fig. 4g ) and the latency of SRSs in epileptic mice was significantly shorter (P < 0.01; Fig. 4i ). Conversely, overexpression of CNTNAP4 resulted in less frequent SRSs in the LV-CNTNAP4 mice compared with the LV-GFP′ controls (P < 0.05; Fig. 4h) , and the latency of SRSs in epileptic mice was significantly longer (P < 0.05; Fig. 4j ). Additionally, electrophysiological microwire array recording of pilocarpine-induced epileptic mice verified the epileptic discharges and SRS of EEG recordings during the interictal and ictal stages (Fig. 4m-o) .
Further, we investigated the pathological lesions using immunohistochemical staining (Zhang et al. 2014; see Supplementary Methods) in the hippocampus and cortex of epileptic mice after injecting LV-CNTNAP4-RNAi and LV-CNTNAP4 (see Supplementary Fig. S4 ). NeuN and GFAP immunostaining demonstrated the absence of significant difference between the LV-CNTNAP4-RNAi/LV-CNTNAP4 groups and the corresponding control groups in the cortex of epileptic mice (see Supplementary Fig. S4a,b) . In the CA3 region of hippocampus, staining for NeuN in the LV-CNTNAP4-RNAi group was significantly lower than that in the LV-GFP group, but significantly higher in the LV-CNTNAP4 group (P < 0.05; see Supplementary  Fig. S4c) ; GFAP immunostaining was significantly increased in the LV-CNTNAP4-RNAi group, but remarkably decreased in the LV-CNTNAP4 group (P < 0.05; see Supplementary Fig. S4d ).
Patch-clamp Analysis
We utilized whole-cell patch clamping to further study the effect of CNTNAP4 on neuronal excitatory and inhibitory synaptic transmission in Mg
2+
-free epilepsy cell model 14 days Figure 2 . Expression of CNTNAP4 in PTZ and pilocarpine-induced epileptic mice. CNTNAP4 mRNA expression in the temporal cortex and hippocampus in the PTZ kindling epileptic mice (a) and in the SRSs mice of pilocarpine-induced epilepsy models (b) was significantly lower than that of the control group (n = 5 in each group).
The expression of CNTNAP4 protein in the temporal cortex and hippocampus in the PTZ kindling epileptic mice (c and d) and in the SRSs mice of pilocarpine-induced epilepsy (e and f) was also significantly lower than that of the control group (n = 6 in each group). Immunofluorescence staining showed CNTNAP4 co-localized with MAP2 in the temporal cortex and hippocampus in epileptic mice, but did not co-localize with GFAP (g and h). CNTNAP4 also co-localized with GAD67 and Gephyrin (j), but did not co-localize with VGLUT1 and PSD95 (i and k). Scale bar 50 μm. *P < 0.05, **P < 0.01.
after LV-CNTNAP4-RNAi or LV-CNTNAP4 injection. To measure neuronal excitability, we recorded the AP under various experimental conditions (Fig. 5a ). The AP frequency in the LV-CNTNAP4-RNAi group was significantly higher than that in the LV-GFP group (P < 0.01; Fig. 5a ), while LV-CNTNAP4 was significantly lower (P < 0.05; Fig. 5a ). To assess inhibitory synaptic transmission, we recorded the mIPSC following lentivirus infection. The amplitude of mIPSC was significantly decreased in the LV-CNTNAP4-RNAi group (P < 0.05; Fig. 5b ), but remarkably increased in the LV-CNTNAP4 group (P < 0.05; Fig. 5b ). The frequency of mIPSC did not show any statistical difference among the examined groups (Fig. 5b) . Further, there was no significant difference in the frequency or the amplitude of mEPSC between the LV-CNTNAP4-RNAi/LV-CNTNAP4 groups and the corresponding control groups (Fig. 5c) . Similarly, there were no significant differences among any of the examined groups with Figure 3 . Impact of LV-CNTNAP4-RNAi and LV-CNTNAP4 on the hippocampal neurons and CNTNAP4 expression in mice. (a) GFP fluorescence was detected in the mouse hippocampus at day 14 following lentiviral infection; Scale bars are 500 μm and 100 μm. Compared with the control group, mice with LV-CNTNAP4-RNAi injection showed significantly lower expression of CNTNAP4 mRNA (b) and lower expression of CNTNAP4 protein (c). Conversely, mice infected with LV-CNTNAP4 showed significantly higher expression of CNTNAP4 mRNA (b) and higher expression of CNTNAP4 protein (d) (n = 5 in each group). Six weeks after the injection of lentiviral vectors, the expression of CNTNAP4 protein in LV-CNTNAP4-RNAi group was significantly lower than controls (e) (n = 6), while that in LV-CNTNAP4 group was significantly higher than control (f) (n = 6). *P < 0.05, **P < 0.01. regard to PPR (Fig. 5e) , which may reflect presynaptic release in inhibitory synapses. Additionally, following the selective blocking of phasic GABA-ergic synaptic current with gabazine, CNTNAP4 failed to alter the tonic GABA-ergic mIPSC amplitude (Fig. 5d) , suggesting that CNTNAP4 may affect the phasic GABAergic synaptic current rather than the tonic GABA-ergic current.
Effect of LV-CNTNAP4-RNAi and LV-CNTNAP4 on GABA A Receptors
To investigate the mechanism by which CNTNAP4 affects the inhibitory postsynaptic current in epilepsy, we investigated the GABA A Rβ2/3 pathway, which predominantly mediates mIPSC in the hippocampus, in pilocarpine-induced epilepsy mice following lentiviral intervention (Pirker et al. 2000; Houston et al. 2008; Hentschke et al. 2009 ). Western blot analysis demonstrated that there were no difference in the expression level of total GABA A Rβ2/3 protein in the hippocampus between the LV-CNTNAP4-RNAi group and the LV-GFP group (P > 0.05; Fig. 6a) . Similarly, we did not observe a difference in the total GABA A Rβ2/3 levels between the LV-CNTNAP4 group and LV-GFP' group (P > 0.05; Fig. 6b ). On the contrary, the expression level of GABA A Rβ2/3 membrane protein was significantly lower in the LV-CNTNAP4-RNAi group compared with the control LV-GFP group (P < 0.05; Fig. 6c ), while GABA A Rβ2/3 membrane protein expression was significantly higher in the LV-CNTNAP4 Figure 4 . Effect of LV-CNTNAP4-RNAi and LV-CNTNAP4 on epileptic mice. The behavioral observation data for PTZ kindling epileptic mice model (a) and the pilocarpine-induced epilepsy model (f) were collected. In the PTZ kindling epileptic model, mice infected with LV-CNTNAP4-RNAi showed higher daily seizure scores compared with control mice (b), the latency of kindling in the epileptic model was significantly shorter than that in controls (d). Mice infected with LV-CNTNAP4 showed a lower daily seizure scores compared with the control mice (c), and the latency of kindling in the epileptic model was significantly longer than that in controls (e) (n = 7 or n = 8 in each group). In the pilocarpine-induced epilepsy model, mice with LV-CNTNAP4-RNAi injection showed more frequent SRSs than the control group (g), and the latency of SRSs in the epileptic model was significantly shorter than that in controls (i). In contrast, mice with LV-CNTNAP4 injection showed less frequent SRSs than control mice (h), and the latency of SRSs in epileptic model was significantly longer than that in controls (j) (n = 7-9 per group). The frequency of action potentials in the LV-CNTNAP4-RNAi group was significantly higher than that in the LV-GFP group, while LV-CNTNAP4 infection resulted in the decrease of the action potentials frequency (n = 5 or n = 6 in each group). (b) The amplitude of miniature inhibitory postsynaptic currents (mIPSC) was significantly decreased in the LV-CNTNAP4-RNAi group, but remarkably increased in the LV-CNTNAP4 group ( n = 5 in each group).
There was no difference in the frequency of mIPSC between these 2 groups (n = 5 or n = 6 in each group). (c) There was no difference in the amplitude or frequency of mEPSC between the LV-CNTNAP4-RNAi/LV-CNTNAP4 groups and the corresponding control groups (n = 5 or n = 6 in each group). (d) After selectively blocking the phasic GABA-ergic synaptic current with gabazine, there was no difference in the tonic GABA-ergic mIPSC amplitude between the LV-CNTNAP4-RNAi group, the LV-CNTNAP4 group and the corresponding control groups (n = 5 in each group). (e) There was no difference in paired pulse ratio (PPR) between the LV-CNTNAP4-RNAi group and LV-GFP group or between the LV-CNTNAP4 group and LV-GFP' group (n = 5 in each group). *P < 0.05, **P < 0.01. Figure 6 . Effect of CNTNAP4 on GABAARβ2/3 in pilocarpine-induced epilepsy model. (a) There was no significant difference in the expression of total GABAARβ2/3 protein in the hippocampus between the LV-CNTNAP4-RNAi group and control group (n = 6 in each group). (b) There was no significant difference in the expression of total GABA A Rβ2/3 protein in the hippocampus between the LV-CNTNAP4 group and controls (n = 6 in each group). (c) The expression of GABA A Rβ2/3 membrane protein in the LV-CNTNAP4-RNAi group was significantly lower than that in control mice (n = 6 in each group). (d) The expression of GABA A Rβ2/3 membrane protein in the LV-CNTNAP4 group was significantly higher than that in the corresponding controls (n = 6 in each group). (e-g) Co-immunoprecipitation analysis demonstrated the presence of protein-protein interactions between CNTNAP4, GABA A Rβ2/3 and GABARAP in the hippocampus tissue of epileptic mice. *P < 0.05. group (P < 0.05; Fig. 6d ). Co-immunoprecipitation analysis showed probable protein-protein interactions between CNTNAP4, GABA A Rβ2/3, and gamma-aminobutyric acid receptor-associated protein (GABARAP) (Fig. 6e-g ) in the hippocampi of epileptic mice. Taken together, these results suggest that CNTNAP4 might affect the transport of GABA A Rβ2/3 via interaction with GABARAP, and the abnormal expression of membrane protein could further influence mIPSC.
Discussion
Several genes, including PIGC, GOSR2, PLA2G6 and SACS, have been associated with the occurrence and development of epilepsy (Dibbens and Rubboli 2016; Edvardson et al. 2016; Gao et al. 2016; Nascimento et al. 2016) . In the present study, we investigated the role of CNTNAP4 in epilepsy. Our results demonstrated that protein and mRNA expression of CNTNAP4 was decreased in the temporal neocortex (resected epileptic focus) obtained from TLE patients. It is worth mentioning that due to ethical reasons, we could not acquire hippocampal tissues from patients and thus we could not examine the expression of CNTNAP4 in the hippocampus. Therefore, we investigated the CNTNAP4 expression in epileptic mice models. In PTZ and pilocarpine epileptic mouse models, results demonstrated decreased CNTNAP4 expression levels in the cortices and hippocampi of epileptic mice. In addition, we investigated the expression of the GABA A R protein in the neocortex of TLE patients as well as the cortices and hippocampi of epileptic mice (see Supplementary Fig. S1 ). Our results demonstrated the increased expression of GABA A R in epileptic tissues. Upregulated expression of the GABA A R may represent a selfprotecting mechanism in epilepsy (Pirker et al. 2003; Li et al. 2017) . These results validate the decreased CNTNAP4 expression detected in epileptic tissues.
CNTNAP4 protein belongs to the neurexin superfamily and members of this family function as cell adhesion molecules and receptors in the vertebrate nervous system with an important role in inhibitory synaptic functions (Spiegel et al. 2002; Huang et al. 2010; Karayannis et al. 2014) . In our study, we observed that CNTNAP4 protein co-localized with inhibitory neuronal synapses in brain tissues of TLE patients and epileptic mice. These findings suggest that decreased expression of CNTNAP4 may be involved in the development of epilepsy, owing to its role in inhibitory synaptic functions. Therefore, it is plausible to speculate that dowenregulation of CNTNAP4 expression in epileptic tissues might have been caused by the decreased inhibitory synaptic functions in epilepsy.
In order to investigate the role of CNTNAP4 in epilepsy, we used lentiviral vectors to knock-down or overexpress CNTNAP4 in the hippocampus. Following 14 days of lentiviral infection, we induced epilepsy in mice by PTZ or pilocarpine treatment. Results demonstrated that the down-regulation of CNTNAP4 increased animal susceptibility to epilepsy; nevertheless, overexpression of CNTNAP4 decreased susceptibility to epilepsy. Previous reports indicated that CNTNAP4 gene may be associated with autism (Wang et al. 2010; O'Roak et al. 2012) , and CNTNAP4 knock-out mice exhibit autistic-like behaviors (Karayannis et al. 2014) . Furthermore, accumulating evidence suggest a common developmental mechanism between epilepsy and autism spectrum disorders (Brooks-Kayal 2010; Tuchman et al. 2010) . A recent study observed that CNTNAP2 knock-out mice show deficits in 3 core autism spectrum disorders behavioral domains, as well as hyperactivity and epileptic seizures (Penagarikano et al. 2011 ). The structural organization of encoded CNTNAP4 polypeptides is highly similar to that of CNTNAP2 (Spiegel et al. 2002) . In concurrence with previous reports, our results demonstrated that CNTNAP4 may influence the development of epilepsy. In addition, we observed that the overexpression of CNTNAP4 could reduce the hippocampal pathological damage in epileptic mice, while down-regulation of CNTNAP4 had opposing actions (see Supplementary Fig. S4 ). Taken together, we demonstrated that alterations in endogenous expression of CNTNAP4 in the hippocampus result in altered epileptic behavior in mice. Additionally, our results demonstrated that CNTNAP4 might exert a protective effect against the development of epilepsy.
In the present study, whole-cell patch-clamp was used to detect neuronal electrophysiological changes in Mg 2+ -free epilepsy cell model of hippocampal slices after knock-down or overexpression of CNTNAP4. Knock-down of CNTNAP4 led to increased AP frequency and decreased mIPSC amplitude, with opposing changes observed upon CNTNAP4 overexpression. Conversely, altering the endogenous expression of CNTNAP4 had no effect on mEPSC, PPR, and tonic GABA-ergic currents, which have been reported to be mediated by extrasynaptic GABA A receptors (Yague et al. 2013 ). These results suggest that CNTNAP4 can affect the excitability of neurons and affect the inhibitory synaptic transmission via postsynaptic intrasynaptic receptors in an epileptic cell model of hippocampus slices. Recent studies also demonstrated that CNTNAP4 is involved in GABAergic synaptic transmission, and spontaneous inhibitory postsynaptic currents (sIPSCs) from cortical pyramidal cells were decreased in CNTNAP4 knock-out mice (Karayannis et al. 2014) . GABA is an important inhibitory neurotransmitter, and it functions by interacting with postsynaptic GABA A receptor and presynaptic GABA B receptor. Clinical studies showed that GABA A receptor agonists, such as benzodiazepines and barbiturates, have the ability to terminate epileptic seizures, whilst GABA B receptor agonists, such as baclofen, aggravate hyperexcitability, and seizure events. Furthermore, experimental evidence suggested that GABA plays a vital role in the pathogenic and therapeutic mechanisms of epilepsy, and GABA A receptor agonists can enhance GABA-mediated inhibition (Treiman 2001) . Thus, we speculated that CNTNAP4 may influence the excitability of neurons and mIPSC by regulating postsynaptic GABA A receptors in epilepsy.
Given the above-mentioned findings, we investigated the expression of the GABA A Rβ2/3 in an epileptic mice model. GABA A Rβ2/3 are the predominantly expressed subunits of GABA A R in the hippocampus and dentate gyrus that mediates inhibitory synaptic transmission (Sperk et al.1997; Pirker et al. 2000; Houston et al. 2008; Hentschke et al. 2009 ). Absence of the β3 subunit weakened the mIPSCs mediated by GABA A R in the CA1 pyramidal neurons, furthermore, GABA A Rβ2/3 displayed a strong and long-lasting inhibition (Sperk et al. 1997) . We observed that down-regulation of CNTNAP4 reduced the expression of GABA A Rβ2/3 membrane protein, while the overexpression of CNTNAP4 had opposing actions. It is worth mentioning that both lentiviral constructs had no effect on the total GABA A Rβ2/3 proteins. This finding indicated CNTNAP4 targets the transport process of GABA A R. To further investigate this mechanism, we used co-immunoprecipitation to analyze protein-protein interactions. We detected interactions between CNTNAP4, GABA A Rβ2/3, and GABARAP in the hippocampus tissue of epileptic mice. The N-terminus of GABARAP is positively charged and shares sequence similarity with microtubuleassociated proteins. GABARAP is a crucial protein for the transport of GABA A R from intracellular vesicles to the cell membrane, and binds with GABA A R and hence affects the expression of receptors (Chen et al. 2007; Weiergraber et al. 2008) . Our findings support the notion that CNTNAP4 may affect the transport of GABA A Rβ2/3 by interacting with GABARAP in epilepsy. This will ultimately influence the expression of GABA A Rβ2/3 membrane proteins and mIPSC. Taken together, the altered expression of GABA A Rβ2/3 membrane protein following altering endogenous CNTNAP4 expression may affect inhibitory postsynaptic currents and neuronal excitability. Therefore, it is plausible to speculate that CNTNAP4 is involved in the development of epilepsy via GABA A Rβ2/3 mediated pathway.
CNTNAP4 can bind with the PDZ domain of various proteins, which can affect the formation of protein complexes (Fanning and Anderson 1999) , the structure of cell membrane (GonzalezMariscal et al. 2000) , the accumulation of membrane receptors (Sheng and Pak 2000) , transport of membrane proteins (Garner et al. 2000) , and production of multi-protein signaling complexes (Scott and Zuker 1998) . Therefore, it is conceivable that other downstream target molecules may be involved in the interaction between CNTNAP4, GABA A Rβ2/3 and GABARAP in epilepsy. However, the exact molecular mechanism will be the focus of future research.
In conclusion, in this study, we demonstrated that CNTNAP4 was decreased in patients with TLE as well as epileptic mice. Lentivirus-mediated knock-down or overexpression of CNTNAP4 in the mice hippocampi altered their susceptibility to epilepsy. CNTNAP4 affected the neuronal excitability and inhibitory synaptic transmission via the postsynaptic GABA A R. Further, CNTNAP4 regulated the expression of GABA A R membrane proteins possibly through affecting the transport of GABA A R by interacting with GABARAP in epilepsy. We demonstrated for the first time that CNTNAP4 plays a crucial role in the occurrence and development of epilepsy through the regulation of GABA A R function. This finding may prove instrumental in uncovering new target molecules for the treatment of epileptic seizures. However, the exact molecular mechanism underlying the interaction between CNTNAP4, GABA A R or the inhibitory synaptic transmission should be further explored in future studies.
